The U.K.’s Technology Strategy Board has awarded £900,000 ($1.39 million) toward a £1.4 million ($2.17 million) research consortium that will work to develop methods of characterizing stem cells through protein fingerprints predictive of changes in stem cell behavior. The consortium will be led by Cellzome, with members that include Plasticell, the University of Sheffield, and Neusentis, Pfizer’s U.K.-based pain, sensory disorders, and regenerative medicine research unit.
“The research will address a critical issue in human stem cell research, with downstream applications in regenerative medicine and cellular therapies,” remarks Dennis Saw, CEO of Plasticell.
The Technology Strategy Board is a business-led government body sponsored by the Department for Business, Innovation and Skills, and created to ensure U.K. global leadership in innovation by supporting projects deemed to create economic growth.